CN121487964A - 抗原纤维抗体 - Google Patents

抗原纤维抗体

Info

Publication number
CN121487964A
CN121487964A CN202480038031.8A CN202480038031A CN121487964A CN 121487964 A CN121487964 A CN 121487964A CN 202480038031 A CN202480038031 A CN 202480038031A CN 121487964 A CN121487964 A CN 121487964A
Authority
CN
China
Prior art keywords
seq
monoclonal antibody
domain
sequence identity
humanized monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480038031.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·B·佩皮斯
D·兰利
J·杰克逊
J·W·韦德
D·克里斯特
J·亨利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amutelin Co ltd
Original Assignee
Amutelin Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Application filed by Amutelin Co ltd filed Critical Amutelin Co ltd
Publication of CN121487964A publication Critical patent/CN121487964A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202480038031.8A 2023-06-14 2024-06-13 抗原纤维抗体 Pending CN121487964A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GB2308884.2 2023-06-14
GB2308898.2 2023-06-14
PCT/EP2024/066449 WO2024256583A1 (fr) 2023-06-14 2024-06-13 Anticorps anti-fibrilles

Publications (1)

Publication Number Publication Date
CN121487964A true CN121487964A (zh) 2026-02-06

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480038031.8A Pending CN121487964A (zh) 2023-06-14 2024-06-13 抗原纤维抗体

Country Status (9)

Country Link
EP (1) EP4727650A1 (fr)
JP (1) JP2026520213A (fr)
KR (1) KR20260026033A (fr)
CN (1) CN121487964A (fr)
AU (1) AU2024304161A1 (fr)
CL (1) CL2025003893A1 (fr)
IL (1) IL325202A (fr)
MX (1) MX2025014924A (fr)
WO (1) WO2024256583A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202418667D0 (en) * 2024-12-19 2025-02-05 Immutrin Ltd Anti-fibril antibodies with engineered Fc regions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
CA2090473A1 (fr) 1990-08-29 1992-03-01 Robert M. Kay Recombinaison homologue dans des cellules mammaliennes
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
PE20161093A1 (es) * 2013-12-20 2016-10-23 Neurimmune Holding Ag Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma
CN106574258B (zh) * 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
SG11202002489YA (en) * 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
WO2022094152A1 (fr) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anticorps anti-transthyrétine et méthodes d'utilisation associées

Also Published As

Publication number Publication date
WO2024256583A1 (fr) 2024-12-19
MX2025014924A (es) 2026-02-03
EP4727650A1 (fr) 2026-04-22
AU2024304161A1 (en) 2025-12-11
CL2025003893A1 (es) 2026-01-30
IL325202A (en) 2026-02-01
JP2026520213A (ja) 2026-06-22
KR20260026033A (ko) 2026-02-25

Similar Documents

Publication Publication Date Title
JP7667823B2 (ja) 抗ｌｒｐ５／６抗体及び使用方法
JP7061875B2 (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
TWI703156B (zh) 抗ａｌｋ２抗體
CN111655729B (zh) 抗卷曲蛋白抗体和使用方法
TWI866304B (zh) 抗EphA4抗體
KR101589135B1 (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
TW200840592A (en) New Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
JP6942358B2 (ja) Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
TW201132353A (en) WISE binding agents and epitopes
JP6236478B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
AU2018219595A1 (en) Anti human annexin A1 antibody
JP2021520195A (ja) Ｃ３結合薬及びその使用方法
TW202000230A (zh) 治療性抗sPLA2-GIB抗體及其用途
KR20240042443A (ko) 신경계 질환을 치료하는 방법
CN111315775A (zh) Angptl8-结合剂及其使用方法
EP4727650A1 (fr) Anticorps anti-fibrilles
JP2022549504A (ja) グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
JP7010491B2 (ja) ヒト化抗ｒａｇｅ抗体
JP2017528523A (ja) 線維性疾患の治療
JP7811544B2 (ja) グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
TW202544048A (zh) 新穎預靶向抗體及其用途
TW202241503A (zh) 肌肉萎縮性側索硬化症之治療用醫藥組合物
HK40012383B (en) Anti human annexin a1 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination